Side-by-side IPO readiness, funding history, and valuation comparison. Data sourced by TechStackIPO.
Scores, valuations, and signals for Nimbus Therapeutics, SpaceX, and 370+ companies. 5-min read every Tuesday.
Nimbus Therapeutics uses structure-based drug design and computational tools to develop precision medicines for challenging targets including NASH, oncology, and immunology. Valued at $2B with $500M raised, Nimbus has multiple clinical-stage programs and partnerships with Takeda and Eli Lilly. Major healthtech IPO candidate as computational drug design matures into commercial medicine.
| Industry | Biotechnology |
| Stage | Series E |
| IPO Status | Private |
| Valuation | $2B |
| Total Funding | $637M |
| Headquarters | Cambridge, MA |
Aerospace and space transportation company. S-1 CONFIRMED filed May 20, 2026 (CIK 0001181412). Roadshow starts June 8, 2026. IPO target June 18–30, 2026. $75B raise at $275B valuation — largest IPO in history. Lead underwriters: Morgan Stanley, Goldman Sachs, JPMorgan. 30% retail allocation. Government contracts: NASA, DoD, Space Force. Starlink: 10M+ subscribers, $10B+ revenue.
| Industry | Aerospace & Defense |
| Stage | Pre-IPO |
| IPO Status | Pre-IPO |
| Valuation | $1.75T\u2013$2T |
| Total Funding | $11.9B |
| Headquarters | Starbase, TX |
Nimbus Therapeutics is valued at $2B. SpaceX is valued at $1.75T\u2013$2T. Both valuations are based on the most recent private funding rounds tracked by TechStackIPO.
Nimbus Therapeutics has raised $637M. SpaceX has raised $11.9B.
Nimbus Therapeutics is currently private. SpaceX is currently pre-IPO. Track both on TechStackIPO for S-1 filings and IPO announcements.
Nimbus Therapeutics operates in Biotechnology, while SpaceX operates in Aerospace & Defense.
Nimbus Therapeutics is a Biotechnology company valued at $2B with $637M raised. SpaceX is a Aerospace & Defense company valued at $1.75T\u2013$2T with $11.9B raised. See TechStackIPO's full side-by-side comparison for IPO readiness scores, funding timelines, and investor data.
Accredited investors can access pre-IPO shares in Nimbus Therapeutics and SpaceX through secondary market platforms, pre-IPO funds, and broker-dealer platforms that facilitate private company transactions. TechStackIPO's marketplace section tracks available access options for both companies. Pre-IPO investments carry higher risk and limited liquidity.